Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy

Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy

Lymphoma

Ruijin Hospital,

affiliated with Shanghai Jiao Tong University School of Medicine, announced that with continuous exploration in clinical practice, experts have made progress in CAR-T cell therapy for lymphoma, benefiting an increasing number of patients. This advancement is of significant importance for further promoting and expanding the application of CAR-T therapy, allowing more patients to benefit from it.

Lymphoma

is a malignant tumor originating from the lymphatic hematopoietic system and encompasses a family of nearly a hundred different subtypes. Relapse and drug resistance pose major challenges for patients. CAR-T products have the potential to improve treatment outcomes and facilitate the broader application of CAR-T therapy among a wider range of patients in China.

CAR-T therapy

involves genetically modifying T cells to equip them with the ability to recognize tumors, enabling them to kill cancer cells in the body. If natural T cells can be likened to “ordinary soldiers,” then CAR-T cells can be considered as “special forces.” For cancer patients, the 5-year survival rate is an important milestone and a signal of cancer being cured. Achieving a 5-year survival implies that some cancer patients treated with CAR-T therapy can obtain long-term survival without further anticancer drug treatment, truly achieving the possibility of “cancer being cured.” Aunt Qin, the first patient enrolled in China’s CAR-T registered clinical trial in 2018, has achieved sustained complete remission for over 5 years and is about to enter the 6th year.

100th patient

At Ruijin Hospital, the 100th patient with relapsed/refractory lymphoma treated with CAR-T therapy has achieved complete remission and been discharged. The patient, Ms. Xu (alias), is a 41-year-old woman who now has a healthy complexion. She was initially diagnosed with follicular lymphoma and underwent chemotherapy and targeted therapy. However, the disease relapsed three months later, transforming into high-grade B-cell lymphoma. High-grade B-cell lymphoma is highly malignant with a poor prognosis. Professor Zhao Weili from the Hematology Department at Ruijin Hospital conducted a detailed analysis of Ms. Xu’s condition and developed a treatment plan for her. On November 22, 2023, after receiving CAR-T cell infusion, Ms. Xu showed complete remission of the tumor during the follow-up examinations at one month and three months.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

Email: doctor.huang@globecancer.com

or WhatsApp+8613717959070

The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #RuijinHospital #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

A New Chapter in Survival! A Quadruple Drug Combination Opens Up a New Treatment Pathway for Multiple Myeloma Patients

🌟 *A New Chapter in Survival! A Quadruple Drug Combination Opens Up a New Treatment Pathway for Multiple Myeloma Patients.* 🌟

 

💪Multiple myeloma has long been a challenging disease to treat, but with the development of new drugs and immunotherapy, the prognosis for MM patients has improved significantly. Now, a new study has opened up a fresh avenue of treatment for us!

#NEJM, #Multiple myeloma

🔬 **Research Findings**

According to a report in the New England Journal of Medicine (NEJM), a study has demonstrated that daratumumab, targeting the CD38 molecule, combined with VRd (referred to as the D-VRd regimen), shows promising safety and efficacy for newly diagnosed multiple myeloma patients eligible for transplantation (NDMM).

 

📊 **Study Results**

After a median follow-up of 47.5 months, the D-VRd group had a lower risk of disease progression or death compared to the VRd group. At 48 months, the progression-free survival rate for the D-VRd group reached 84.3%, significantly higher than the 67.7% in the VRd group (P＜0.001). Additionally, the D-VRd group had significantly higher rates of complete response and deeper response compared to the VRd group, with a higher MRD negativity rate as well.

 

💡 **Conclusion**

This study indicates that the D-VRd regimen brings significant benefits to newly diagnosed multiple myeloma patients, including prolonged progression-free survival, higher rates of response, and MRD negativity. This combined therapy has the potential to become a new frontline treatment for multiple myeloma, offering patients longer survival and improved quality of life!

 

🔍 **Learn More**

For more information on the latest treatment advances and research findings in multiple myeloma, stay tuned to our page!

 

📚We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.

We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

 

doctor.huang@globecancer.com

WhatsApp+8613717959070

 

#MultipleMyeloma #NewTreatmentApproach #HealthScience #MedicalResearch